Active, not recruitingPhase 2NCT03834961
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Studying Fibrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Theodore W Laetsch, MDChildren's Oncology Group
- Intervention
- Larotrectinib Sulfate(drug)
- Enrollment
- 33 target
- Eligibility
- 30 years · All sexes
- Timeline
- 2019 – 2027
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States
- Yale University, New Haven, Connecticut, United States
- Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Broward Health Medical Center, Fort Lauderdale, Florida, United States
- Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03834961 on ClinicalTrials.govOther trials for Fibrosarcoma
Additional recruiting or active studies for the same condition.